Our asset has demonstrated preclinical antifibrotic activity in skin, pulmonary, and liver fibrosis; healing effect in skin wound healing models; and antitumor activity in colorectal and breast cancer models.
Target indications were chosen because fibrosis, aberrant wound healing, and cancer, share many cellular processes such as cell migration, epithelial-mesenchymal transition, and extracellular matrix deposition, as well as a common driver: TGF-β
DISCOVERY & CHARACTERIZATION
PROOF OF CONCEPT STUDIES
PRECLINICAL CMC / GLP-TOX
Inhibitor of TGF-β signaling pathway